Cargando…

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect

Deutetrabenazine (Austedo, Teva), an approved treatment of chorea in Huntington's disease and tardive dyskinesia in adult patients, is a rationally designed deuterated form of tetrabenazine. Two studies assessed the pharmacokinetics and safety of deutetrabenazine compared with tetrabenazine, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Frank, Stamler, David, Bradbury, Margaret, Loupe, Pippa S., Hellriegel, Edward, Cox, Donna S., Savola, Juha‐Matti, Gordon, Mark Forrest, Rabinovich‐Guilatt, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246815/
https://www.ncbi.nlm.nih.gov/pubmed/33038289
http://dx.doi.org/10.1002/cpdd.882
_version_ 1783716390230818816
author Schneider, Frank
Stamler, David
Bradbury, Margaret
Loupe, Pippa S.
Hellriegel, Edward
Cox, Donna S.
Savola, Juha‐Matti
Gordon, Mark Forrest
Rabinovich‐Guilatt, Laura
author_facet Schneider, Frank
Stamler, David
Bradbury, Margaret
Loupe, Pippa S.
Hellriegel, Edward
Cox, Donna S.
Savola, Juha‐Matti
Gordon, Mark Forrest
Rabinovich‐Guilatt, Laura
author_sort Schneider, Frank
collection PubMed
description Deutetrabenazine (Austedo, Teva), an approved treatment of chorea in Huntington's disease and tardive dyskinesia in adult patients, is a rationally designed deuterated form of tetrabenazine. Two studies assessed the pharmacokinetics and safety of deutetrabenazine compared with tetrabenazine, and the effects of food on absorption of the deuterated active metabolites, α‐dihydrotetrabenazine (α‐HTBZ) and β‐dihydrotetrabenazine (β‐HTBZ). One study was an open‐label 2‐part study in healthy volunteers; the first part included a crossover single dose of two 15 mg candidate deutetrabenazine formulations in fed and fasted states compared with tetrabenazine 25 mg in the fasted state, and the second part included single and repeated dosing of the commercial formulation of deutetrabenazine (7.5, 15, and 22.5 mg) compared with tetrabenazine 25 mg. The second study was an open‐label 5‐way crossover study in healthy volunteers (n = 32) to evaluate relative bioavailability of 4 dose levels of the commercial formulation of deutetrabenazine (6, 12, 18, and 24 mg) with a standard meal and 18 mg with a high‐fat meal. Both studies confirmed longer half‐lives for active metabolites and lower peak‐to‐trough fluctuations for the sum of the metabolites (total [α+β]‐HTBZ) following deutetrabenazine compared with tetrabenazine (3‐ to 4‐fold and 11‐fold, respectively) in steady‐state conditions. Deutetrabenazine doses estimated to provide total (α+β)‐HTBZ exposure comparable to tetrabenazine 25 mg were 11.4‐13.2 mg. Food had no effect on exposure to total (α+β)‐HTBZ, as measured by AUC. Although the total (α+β)‐HTBZ C(max) of deutetrabenazine was increased by ≈50% in the presence of food, it remained lower than that of tetrabenazine.
format Online
Article
Text
id pubmed-8246815
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82468152021-07-02 Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect Schneider, Frank Stamler, David Bradbury, Margaret Loupe, Pippa S. Hellriegel, Edward Cox, Donna S. Savola, Juha‐Matti Gordon, Mark Forrest Rabinovich‐Guilatt, Laura Clin Pharmacol Drug Dev Articles Deutetrabenazine (Austedo, Teva), an approved treatment of chorea in Huntington's disease and tardive dyskinesia in adult patients, is a rationally designed deuterated form of tetrabenazine. Two studies assessed the pharmacokinetics and safety of deutetrabenazine compared with tetrabenazine, and the effects of food on absorption of the deuterated active metabolites, α‐dihydrotetrabenazine (α‐HTBZ) and β‐dihydrotetrabenazine (β‐HTBZ). One study was an open‐label 2‐part study in healthy volunteers; the first part included a crossover single dose of two 15 mg candidate deutetrabenazine formulations in fed and fasted states compared with tetrabenazine 25 mg in the fasted state, and the second part included single and repeated dosing of the commercial formulation of deutetrabenazine (7.5, 15, and 22.5 mg) compared with tetrabenazine 25 mg. The second study was an open‐label 5‐way crossover study in healthy volunteers (n = 32) to evaluate relative bioavailability of 4 dose levels of the commercial formulation of deutetrabenazine (6, 12, 18, and 24 mg) with a standard meal and 18 mg with a high‐fat meal. Both studies confirmed longer half‐lives for active metabolites and lower peak‐to‐trough fluctuations for the sum of the metabolites (total [α+β]‐HTBZ) following deutetrabenazine compared with tetrabenazine (3‐ to 4‐fold and 11‐fold, respectively) in steady‐state conditions. Deutetrabenazine doses estimated to provide total (α+β)‐HTBZ exposure comparable to tetrabenazine 25 mg were 11.4‐13.2 mg. Food had no effect on exposure to total (α+β)‐HTBZ, as measured by AUC. Although the total (α+β)‐HTBZ C(max) of deutetrabenazine was increased by ≈50% in the presence of food, it remained lower than that of tetrabenazine. John Wiley and Sons Inc. 2020-10-10 2021-06 /pmc/articles/PMC8246815/ /pubmed/33038289 http://dx.doi.org/10.1002/cpdd.882 Text en © 2020 Ratiopharm. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Schneider, Frank
Stamler, David
Bradbury, Margaret
Loupe, Pippa S.
Hellriegel, Edward
Cox, Donna S.
Savola, Juha‐Matti
Gordon, Mark Forrest
Rabinovich‐Guilatt, Laura
Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
title Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
title_full Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
title_fullStr Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
title_full_unstemmed Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
title_short Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
title_sort pharmacokinetics of deutetrabenazine and tetrabenazine: dose proportionality and food effect
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246815/
https://www.ncbi.nlm.nih.gov/pubmed/33038289
http://dx.doi.org/10.1002/cpdd.882
work_keys_str_mv AT schneiderfrank pharmacokineticsofdeutetrabenazineandtetrabenazinedoseproportionalityandfoodeffect
AT stamlerdavid pharmacokineticsofdeutetrabenazineandtetrabenazinedoseproportionalityandfoodeffect
AT bradburymargaret pharmacokineticsofdeutetrabenazineandtetrabenazinedoseproportionalityandfoodeffect
AT loupepippas pharmacokineticsofdeutetrabenazineandtetrabenazinedoseproportionalityandfoodeffect
AT hellriegeledward pharmacokineticsofdeutetrabenazineandtetrabenazinedoseproportionalityandfoodeffect
AT coxdonnas pharmacokineticsofdeutetrabenazineandtetrabenazinedoseproportionalityandfoodeffect
AT savolajuhamatti pharmacokineticsofdeutetrabenazineandtetrabenazinedoseproportionalityandfoodeffect
AT gordonmarkforrest pharmacokineticsofdeutetrabenazineandtetrabenazinedoseproportionalityandfoodeffect
AT rabinovichguilattlaura pharmacokineticsofdeutetrabenazineandtetrabenazinedoseproportionalityandfoodeffect